SNY vs. ABT
SNY (Sanofi) and ABT (Abbott Laboratories) are both stocks. Both are in the Healthcare sector — SNY in Drug Manufacturers - General, ABT in Medical Devices. Over the past 10 years, SNY returned 4.52%/yr vs 10.35%/yr for ABT. At a 0.37 correlation, their price movements are largely independent.
Performance
SNY vs. ABT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SNY achieves a -7.72% return, which is significantly higher than ABT's -29.78% return. Over the past 10 years, SNY has underperformed ABT with an annualized return of 4.52%, while ABT has yielded a comparatively higher 10.35% annualized return.
SNY
- 1D
- -1.00%
- 1M
- -2.26%
- YTD
- -7.72%
- 6M
- -10.00%
- 1Y
- -9.09%
- 3Y*
- -1.54%
- 5Y*
- 0.05%
- 10Y*
- 4.52%
ABT
- 1D
- 0.02%
- 1M
- -0.63%
- YTD
- -29.78%
- 6M
- -29.78%
- 1Y
- -33.61%
- 3Y*
- -3.93%
- 5Y*
- -2.65%
- 10Y*
- 10.35%
SNY vs. ABT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | -7.72% | 4.93% | 1.09% | 6.55% | 0.57% | 7.00% | 0.39% | 20.47% | 6.06% | 9.96% |
ABT Abbott Laboratories | -29.78% | 12.87% | 4.81% | 2.26% | -20.68% | 30.53% | 28.04% | 22.08% | 29.06% | 52.03% |
Correlation
The correlation between SNY and ABT is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Jul 2, 2002 | 0.37 |
Fundamentals
SNY:
$102.04B
ABT:
$151.97B
SNY:
$3.09
ABT:
$3.59
SNY:
13.72
ABT:
24.24
SNY:
2.19
ABT:
3.37
SNY:
1.40
ABT:
2.30
SNY:
$47.35B
ABT:
$45.13B
SNY:
$34.18B
ABT:
$25.45B
SNY:
$12.63B
ABT:
$10.80B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SNY vs. ABT — Risk / Return Rank
SNY
ABT
SNY vs. ABT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SNY | ABT | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.37 | -1.41 | +1.04 |
Sortino ratioReturn per unit of downside risk | -0.34 | -1.91 | +1.58 |
Omega ratioGain probability vs. loss probability | 0.96 | 0.74 | +0.21 |
Calmar ratioReturn relative to maximum drawdown | -0.55 | -0.86 | +0.32 |
Martin ratioReturn relative to average drawdown | -1.08 | -2.00 | +0.92 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SNY | ABT | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.37 | -1.41 | +1.04 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.00 | -0.12 | +0.12 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.19 | 0.44 | -0.25 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.20 | 0.49 | -0.29 |
Drawdowns
SNY vs. ABT - Drawdown Comparison
The maximum SNY drawdown since its inception was -46.46%, roughly equal to the maximum ABT drawdown of -45.66%. Use the drawdown chart below to compare losses from any high point for SNY and ABT.
Loading charts...
Drawdown Indicators
| SNY | ABT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -46.46% | -45.66% | -0.80% |
Max Drawdown (1Y)Largest decline over 1 year | -16.70% | -38.99% | +22.29% |
Max Drawdown (3Y)Largest decline over 3 years | -23.37% | -39.64% | +16.27% |
Max Drawdown (5Y)Largest decline over 5 years | -33.52% | -39.64% | +6.12% |
Max Drawdown (10Y)Largest decline over 10 years | -33.52% | -39.64% | +6.12% |
Current DrawdownCurrent decline from peak | -21.40% | -36.40% | +15.00% |
Average DrawdownAverage peak-to-trough decline | -12.19% | -10.83% | -1.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.44% | 16.86% | -8.42% |
Volatility
SNY vs. ABT - Volatility Comparison
The current volatility for Sanofi (SNY) is 5.44%, while Abbott Laboratories (ABT) has a volatility of 7.34%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than ABT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SNY | ABT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.44% | 7.34% | -1.90% |
Volatility (6M)Calculated over the trailing 6-month period | 14.97% | 18.93% | -3.96% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.95% | 23.96% | +0.99% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.68% | 21.97% | +2.71% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.42% | 23.63% | -0.21% |
Dividends
SNY vs. ABT - Dividend Comparison
SNY's dividend yield for the trailing twelve months is around 5.72%, more than ABT's 2.80% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABT Abbott Laboratories | 2.80% | 1.88% | 1.95% | 1.85% | 1.71% | 1.28% | 1.32% | 1.47% | 1.55% | 1.86% | 2.71% | 2.14% |
SNY Sanofi | 5.72% | 4.56% | 4.22% | 3.83% | 4.32% | 3.80% | 3.61% | 3.47% | 4.29% | 3.82% | 4.11% | 3.77% |
Financials
SNY vs. ABT - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and Abbott Laboratories. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNY vs. ABT - Profitability Comparison
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.
ABT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a gross profit of 6.28B and revenue of 11.16B. Therefore, the gross margin over that period was 56.3%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.
ABT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported an operating income of 1.84B and revenue of 11.16B, resulting in an operating margin of 16.5%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.
ABT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a net income of 1.08B and revenue of 11.16B, resulting in a net margin of 9.7%.
Frequently Asked Questions
SNY and ABT have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ABT has higher volatility (7.34%) compared to SNY (5.44%). In terms of maximum drawdown, SNY dropped -46.46% vs ABT's -45.66%.
SNY currently has the higher Sharpe Ratio (-0.37 vs -1.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SNY and ABT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer